Breadcrumb Home Business activities Â鶹Éç BioCapital Â鶹Éç Biocapital Portfolio Spero Therapeutics Spero Therapeutics Spero has a pipeline of novel treatments for multi-drug resistant (MDR) bacterial infections. Two programs are in clinical phase I Relateret nyheder om Spero Therapeutics 28 May 2025 Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee 14 May 2025 Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update 28 March 2025 Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update 3 October 2024 Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy 6 August 2024 Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update Â鶹Éç BioCapital Invested 2015 IPO in 2017 – SPRO (Nasdaq) Location Boston, Massachusetts, USA
